Provided is the use of a complement inhibitor in the preparation of a medicament for preventing or ameliorating an ocular disease associated with complement activation in a subject, wherein the complement inhibitor is an antibody or a binding fragment thereof that specifically binds to C5a. The disease can be age-related macular degeneration (AMD).